AI agents are moving rapidly from experimentation to everyday business use, but choosing the right platform can feel ...

UiPath offers attractive AI automation exposure at a compelling valuation, with shares up ~35% YTD and strong Q3 results fueling momentum. PATH trades at 4.6x EV/FY27 revenue and 18.3x EV/FY27 FCF, ...

UiPath (PATH) just checked several key boxes for investors at once, moving from GAAP losses to profit while accelerating revenue growth and doubling down on its agentic AI and automation platform ...

Palantir has been one of the best growth stories in the market. UiPath is just beginning to see its revenue growth accelerate as it looks to become an AI agent orchestration platform. UIPath's ...

UiPath Inc. (PATH) is one of a bunch of software companies that went public in 2021, saw its shares subsequently collapse, and have seemingly never managed to make a recovery. And to be fair, many of ...

Bullish flow in UiPath (PATH), with shares up 62c, or 3.88%, near $16.75. Options volume roughly in line with average with 54k contracts traded and calls leading puts for a put/call ratio of 0.11, ...

Financing cash flow was -11.17 in the latest quarter, changing by 89.99% compared to the previous quarter. What was UiPath DRC’s levered free cash flow in the latest quarter? Levered free cash flow ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The FDA has approved its first at-home, nondrug therapy for depression, with a wearable brain stimulation headset developed by Flow Neuroscience. The agency issued a green light that covers the device ...

Dec 11 (Reuters) - The U.S. Food and Drug Administration has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to typical antidepressants that ...